Abstract:Background: Tumor necrosis factor receptor superfamily 25 (TNFRSF25) is a T-cell co-stimulatory receptor. Expression of its ligand, TNF-like cytokine 1A (TL1A), on mouse tumor cells has been shown to promote tumor regression. This study aimed to develop TNFRSF25 agonists (both antibodies (Abs) and TL1A proteins) and to investigate their potential antitumor effects. Methods: Anti-mouse TNFRSF25 (mTNFRSF25) Abs and multimeric TL1A proteins were generated as TNFRSF25 agonists. Their agonism was assessed in luciferase reporter and T-cell co-stimulation assays, and their antitumor effects were evaluated in syngeneic mouse tumor models. TNFRSF25 expression within the tumor microenvironment and the effects of an anti-mTNFRSF25 agonistic Ab on tumor-infiltrating T cells were evaluated by flow cytometry. Cell depletion assays were used to identify the immune cell types that contribute to the antitumor effect of the anti-mTNFRSF25 Ab. The Fc gamma receptor (FcγR) dependence of TNFRSF25 agonists was assessed in an in vivo T-cell expansion model and a mouse tumor model using Fc variants and FcγR-deficient mice. Results: TNFRSF25 agonists exhibited antitumor effects in syngeneic mouse tumor models without causing observed side effects. We identified an anti-mTNFRSF25 agonistic Ab, 1A6-m1, which exhibited greater antitumor activity than a higher affinity anti-TNFRSF25 Ab which engages an overlapping epitope with 1A6-m1. 1A6-m1 activated CD8+ T cells and antigen-specific T cells, leading to tumor regression; it also induced long-term antitumor immune memory. Although activating TNFRSF25 by 1A6-m1 expanded splenic regulatory T (Treg) cells, it did not influence intratumoral Treg cells. Moreover, 1A6-m1's antitumor effects required the engagement of both inhibitory FcγRIIB and activating FcγRIII. Replacing 1A6-m1's CH1-hinge region with that of human IgG2 (h2) conferred enhanced antitumor effects. Finally, we also generated multimeric human and mouse TL1A fusion proteins as TNFRSF25 agonists, and they co-stimulated CD8+ T cells and reduced tumor growth, even in the absence of Fc-FcγR interactions. Conclusion: Our data demonstrates the potential of activating TNFRSF25 by Abs and multimeric TL1A proteins for cancer immunotherapy and provides insights into their development astherapeutics.

Cytotoxicity in L929 murine fibrosarcoma cells after triggering of transfected human p75 tumour necrosis factor (TNF) receptor is mediated by endogenous murine TNF

TUMOUR NECROSIS FACTOR-INDUCED NECROSIS VERSUS ANTI-Fas-INDUCED APOPTOSIS IN L929 CELLS

Influence of inhibitor of signal transduction on the cell apoptosis induced by TNF β

The Diversity and Similarity of Transmembrane Trimerization of TNF Receptors

Identification And Characterization Of A Membrane-Bound Cyto-Toxin Of Murine Cytolytic Lymphocytes That Is Related To Tumor Necrosis Factor Cachectin

Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice.

Biological Activities of Human Tumor Necrosis Factor-Alpha and Its Novel Mutants.

Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8+ T cells and inhibited tumor growth

Fusion Protein of CDR Mimetic Peptide with Fc Inhibit TNF-α Induced Cytotoxicity

Murine monoclonal antibodies defining neutralizing epitopes on tumor necrosis factor

Altered susceptibility to tumor necrosis factor alpha-induced apoptosis of mouse cells expressing polyomavirus middle and small T antigens

TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity

A functional recombinant single-chain T cell receptor fragment capable of selectively targeting antigen-presenting cells

70 kDa heat shock cognate protein is a transformation-associated antigen and a possible target for the host's anti-tumor immunity.

Cloning of Murine BRI3 Gene and Study on Its Function for Inducing Cell Death

TNF-induced necroptosis in L929 cells is tightly regulated by multiple TNFR1 complex I and II members

Mts1 (S100A4) and Its Peptide Demonstrate Cytotoxic Activity in Complex with Tag7 (PGLYRP1) Peptide

A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor

Expression of modified FcγRI enables myeloid cells to elicit robust tumor-specific cytotoxicity

NF-κB Signaling and Cell-Fate Decision Induced by a Fast-Dissociating Tumor Necrosis Factor Mutant.

Constitutive expression of human hsp27, Drosophila hsp27, or human alpha B-crystallin confers resistance to TNF- and oxidative stress-induced cytotoxicity in stably transfected murine L929 fibroblasts.